Tag Archives: plus

Should Macitentan Plus Riociguat Be Used as First-Line Therapy in PAH?

February 07, 2019 Share this content: Improvements in 6-minute walking distance scores and WHO functional class categories were seen in patients with PAH treated with macitentan plus riociguat. Upfront combination therapy with macitentan plus riociguat has demonstrated effectiveness in patients with pulmonary arterial hypertension (PAH), according to the results of a small retrospective, open-label cohort… Read More »

FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Print this page HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of leukemia in adults.1 This is… Read More »